Clinical Trials Logo

Filter by:
NCT ID: NCT06247254 Not yet recruiting - Blood Pressure Clinical Trials

Telehealth-Enhanced Assessment and Management

TEAMS-BP
Start date: October 2024
Phase: N/A
Study type: Interventional

TEAMS-BP is a Patient-Centered Outcomes Research Institute (PCORI)-funded trial under the Phased Large Awards for Comparative Effectiveness Research (PLACER) funding mechanism to evaluate two comprehensive and evidence-based strategies for managing blood pressure (BP) following stroke.

NCT ID: NCT06247176 Recruiting - Clinical trials for Autism Spectrum Disorder

Sensory Habituation in Autism Spectrum Disorders

ASD_VR_RE
Start date: January 8, 2024
Phase: N/A
Study type: Interventional

Autism spectrum disorder (ASD) is one of the most common developmental disabilities and often people with ASD have sensory processing disorders. These sensory processing disorders are often associated with problem behaviors and, more recently, have been connected to anxiety disorders in people with ASD. While it has been suggested that sensory processing responses in ASD could be malleable, current treatment strategies for sensory processing disorders in ASD have inconsistent results or lack large-sample sized data. This investigation will explore changes in neurophysiological activity in people with ASD and neurotypical peers after they are exposed to an unpleasant visual stimulus through a virtual reality systematic desensitization protocol. 30 people with ASD and 30 neurotypical people between the ages 7 - 35 will be recruited. The study have, 1) a practice magnetic resonance imaging (MRI) visit with questionnaires, 2) a per-exposure MRI with structural and functional MRI collections, 3) a virtual reality systematic desensitization session where we will record the participant's physiological response using an Emotibit device, and 4) a post-exposure MRI session with structural and functional MRI collections. This investigation aims to quantify changes in neurophysiological responses in order to determine the effect of systematic desensitization.

NCT ID: NCT06247124 Recruiting - HPV Vaccination Clinical Trials

OPERATION WIPE OUT: Multi-Channel Communication Campaign to Promote HPV Vaccination in Chambers County, Alabama

Start date: November 8, 2023
Phase: N/A
Study type: Interventional

The Advisory Committee on Immunization Practices (ACIP) recommends HPV vaccination for all children and adults ages 9 to 26 in the U.S. However, HPV vaccination rates nationally and in Alabama lag far behind the Healthy People 2020 goal of 80% coverage. Despite multiple efforts, Alabama still ranks third in cervical cancer mortality and incidence nationally with great disparities within the state, particularly between urban and rural counties. In order to address this public health challenge, organizations have come together to develop, implement, and evaluate a statewide action plan to eliminate cervical cancer as a public health problem in Alabama by 2033. This plan was officially launched by the State Health Officer in May 2023 as a partnership between government, academia, civic organizations, and non-profit organizations and is known as OPERATION WIPE OUT. The overall goal of this Supplement is to develop, implement, and examine the feasibility and scalability of a theory-driven, participatory multi-channel communication campaign to promote HPV vaccination uptake that is designed and delivered by high school students with the support of OPERATION WIPE OUT partners and linked to school-based vaccination in a rural county that has the highest cervical cancer incidence in the state (Chambers County). The specific aims are: (1) To develop and examine the feasibility of a theory-driven, participatory multi-channel communication campaign to promote HPV vaccination uptake with high school students being agents of change and provision of school-based vaccination; and (2) To examine specific features of the multi-channel communication campaign regarding scalability, sustainability, and potentially a future full-scale implementation science trial. The primary outcome will be HPV vaccination uptake at the county level obtained Alabama Department of Public Health Vaccination Registry (ImmPRINT). Additionally, treatment fidelity and scalability assessments will be conducted to inform sustainability efforts.

NCT ID: NCT06247111 Not yet recruiting - Hypertension Clinical Trials

Monitoring Blood Pressure at Home

Start date: June 2024
Phase: N/A
Study type: Interventional

The overall goal of this project is to determine if measuring blood pressure at home and staying in contact with a team of pharmacists and physicians to manage your blood pressure is feasible. The study will enroll 24 participants at UAB. Half of the participants (12 patients) will be asked to measure their blood pressure at home, and half of the participants (12 patients) will continue to receive usual care. Participants who measure their blood pressure at home will also meet with a pharmacist weekly over the phone to discuss blood pressure readings and have blood pressure medications prescribed if needed. This program will last 3 months.

NCT ID: NCT06247098 Recruiting - Dental Implant Clinical Trials

Evaluation of Sinus Augmentation Bone Healing Using Autograft and Xenograft Compared to Xenograft Alone

Start date: September 2024
Phase: N/A
Study type: Interventional

To evaluate bone healing at 4 months after lateral sinus augmentation with a 4:1 ratio of autologous bone and xenograft or xenograft alone. A radiographic volumetric, histomorphometric, and histologic analysis.

NCT ID: NCT06247085 Recruiting - Homocystinuria Clinical Trials

A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment

HARMONY
Start date: December 28, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to measure efficacy and safety of pegtibatinase treatment compared with placebo in participants with classical HCU receiving standard of care who have not achieved tHcy target levels. Study details include: - Total Study duration: up to 38 weeks - Screening: - Initial Screening duration: up to 4 weeks - Pre-treatment Diet Standardization Period duration: up to 6 weeks - Blinded Treatment Duration: 24 weeks - 2-week blinded dose titration period - 22-week blinded assessment period - Safety Follow-Up: 4 weeks after last dose (as applicable for those not enrolling in the long term extension study, ENSEMBLE)

NCT ID: NCT06247072 Completed - Glaucoma Clinical Trials

TRK-3 Conformance to Standards for Tonometers

Start date: February 2, 2024
Phase:
Study type: Observational

To collect measurements of a new tonometer and show conformance to standards for tonometers.

NCT ID: NCT06246968 Recruiting - Breast Cancer Clinical Trials

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

Start date: January 29, 2024
Phase: Phase 1
Study type: Interventional

Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.

NCT ID: NCT06246955 Recruiting - Clinical trials for Malignant Solid Neoplasm

Acceptance and Commitment Therapy and Compassion-Based Virtual Group Therapy to Improve Psychological Wellbeing in Patients With Cancer

Start date: January 8, 2024
Phase: N/A
Study type: Interventional

This clinical trial tests how well acceptance and commitment therapy and compassion based virtual group therapy works to improve psychological wellbeing, such as compassion, understanding, and flexibility, in patients with cancer. Receiving a cancer diagnosis, undergoing cancer treatment, and living with cancer- or treatment-related symptoms have often been found to be associated with elevated distress and decreased quality of life for individuals, even when the disease is stable or in remission. Acceptance and Commitment Therapy (ACT) has demonstrated considerable benefits on individuals' quality of life, psychological flexibility, and amelioration of psychological distress following a cancer diagnosis and in the face of uncertainty, loss, and challenges associated with cancer.

NCT ID: NCT06246903 Enrolling by invitation - Nevi, Dysplastic Clinical Trials

INTER-PATHOLOGIST READER STUDY

Start date: June 15, 2023
Phase:
Study type: Observational

This is a post study histology analysis from previously obtained pathology slides.